Lunit Inc.
Financials
Valuation Metrics
Lunit Inc.'s Market Cap is ₩8451B. At end of 2025 it was ₩1.4T. Ranked #339 of 2,419 in KR market (top 14%), #102 of 1,638 on KOSDAQ (top 6%), #7 of 95 in Health Care Equipment & Services (top 7%) by Market Cap.
Investment Metrics(as of 2026-10-08)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 845.10B KRW | KR#339/2,419 Sec#7/95 |
| Revenue | 91.82B KRW | KR#1,463/2,419 Sec#42/95 |
| Net Income | -55.82B KRW | KR—/2,419 Sec—/95 |
| Total Assets | 545.27B KRW | KR#732/2,419 Sec#12/95 |
| Net Assets | 331.64B KRW | KR#684/2,419 Sec#11/95 |
| Employees | 320 | KR#754/2,419 Sec#20/95 |
| Value | ||
| P/B | 2.55x | KR#2,023/2,419 Sec#71/95 |
| P/S | 9.20x | KR#2,255/2,419 Sec#81/95 |
| FCF Yield | -6.60% | KR—/2,419 Sec—/95 |
| Profitability | ||
| ROE | -16.83% | KR#2,057/2,419 Sec#75/95 |
| ROA | -10.24% | KR#2,109/2,419 Sec#74/95 |
| Op. Margin | -76.55% | KR#2,279/2,419 Sec#83/95 |
| Revenue Growth | 24.27% | KR#468/2,419 Sec#24/95 |
| Financial Health | ||
| Debt Ratio | 64.42% | KR#1,152/2,419 Sec#64/95 |
| Total Debt | 91.78B KRW | KR#760/2,419 Sec#15/95 |
| FCF | -55.81B KRW | KR#2,090/2,419 Sec#81/95 |
| Cash | 154.53B KRW | KR#333/2,419 Sec#3/95 |
| Current Ratio | 1.10x | KR#1,601/2,419 Sec#75/95 |
| Performance | ||
| 1Y Return | -40.58% | KR#1,871/2,419 Sec#66/95 |
| 1M Return | 30.46% | KR#190/2,419 Sec#9/95 |
| From 52W High | -53.77% | KR#1,629/2,419 Sec#56/95 |
| 1Y MDD | -64.20% | KR#1,717/2,419 Sec#61/95 |
| Trading | ||
| Volume | 915,356 shares | KR#130/2,419 Sec#5/95 |
| Trading Value | 10.30B KRW | KR#258/2,419 Sec#5/95 |
| Foreign Own. | 10.26% | KR#469/2,419 Sec#13/95 |
| Per Share | ||
| EPS | -750 KRW | KR—/2,419 Sec—/95 |
| BPS | 4,454 KRW | KR#1,585/2,419 Sec#41/95 |
Company Info
Lunit, established in 2013 and headquartered in Gangnam-gu, Seoul, is a deep learning-based medical artificial intelligence enterprise that entered the U.S. market in 2024 through the acquisition of Volpara. The company develops cancer diagnostic image interpretation solution Lunit INSIGHT and biomarker solution Lunit SCOPE, offering product lines for cancer detection and treatment in chest X-rays and mammography. Lunit also expands its research and development and launches DBT products through partnerships with global manufacturers such as GE Healthcare.